Loading stock data…
$2.08-0.10 (-4.38%)
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases.
BioLineRx Ltd. in the Healthcare sector is trading at $2.08 with a market capitalization of $10M. Wall Street consensus targets $22.00 (2 analysts), implying a +960.2% move over the next 12 months. The stock is currently near its 52-week low of $2.01, remaining 25.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $294,000↓ | $477,000↑ | $194,000↓ | $427,000↑ | $304,000 |
| Gross Profit | $235,000↓ | $382,000↑ | $154,000↓ | $343,000↑ | $232,000 |
| Operating Income | -$3.57M↓ | -$3.00M↑ | -$3.39M↓ | -$2.21M↑ | -$2.30M |
| Net Income | -$3.03M↓ | -$1.60M↓ | -$1.39M↓ | -$977,000↑ | -$3.94M |
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and ...